Research and Development

Context Therapeutics, a biotech company that focuses on the development of treatments for Sigma1-related diseases, has announced that a new …

Specialist medical education company, Wave, has boosted its editorial and programme delivery teams with two new appointments. Sadaf Kazi joins …

The British Pharmacopoeia (BP) 2018 is now published and available for purchase. An essential text for anyone working to develop …

New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication …

GSK continue its appointment spree with a particularly notable staff acquisition, with leading immuno-oncology scientist, Dr Laurie Glimcher, joining its …

The week was characterised by two big psoriasis approval stories, while Amgen’s osteoporosis treatment was knocked back. Novartis CEO Joe …

A blood test has been created that could offer an inexpensive, and less invasive, alternative to current Alzheimer’s disease tests. …

BenevolentAI, a company that uses an artificial intelligence platform to improve drug discovery, has announced the appointment of Nathan Brown …

Daniel Ray, Head of NHS Digital discusses the importance of data usage in the healthcare system and the NHS Digital …

An independent steering committee has compiled a report looking at how more can be delivered from the NHS budget, without …

A collaboration between Swiss antibody therapeutics firm Humab BioMed and the University of California, Berkeley has given rise to an …

The FDA has announced that it has chosen to approve Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Gilead’s investigational drug for the treatment of chronic …

Researchers at the Perelman School of Medicine at the University of Pennsylvania have found that by combining specific hormone-based drugs …

According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …

Jesper Høiland has been revealed as the new President and Chief Executive Officer of Radius. The news comes shortly after …